Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583966 | 0.83 | HSD11B1 (0.38) | SMN1; SMN2OPRM1ALDH1A1HTT | |
| SCHEMBL4807305 | 0.76 | KDM4E (0.51) | KDM4EADAM17LMNAMEN1KMT2A | |
| SCHEMBL4812849 | 0.72 | KDM4E (0.47) | KDM4EADAM17LMNAMEN1KMT2A | |
| SCHEMBL4807371 | 0.71 | KDM4E (0.46) | KDM4EADAM17LMNAMEN1KMT2A | |
| SCHEMBL28964761 | 0.69 | L3MBTL1 (0.53) | KDM4ELMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6627628 | 0.69 | KDM4E (0.64) | KDM4ELMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3718479 | 0.69 | KDM4E (0.64) | KDM4ELMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4811204 | 0.68 | KDM4E (0.46) | KDM4EADAM17LMNAMEN1KMT2A | |
| SCHEMBL4813521 | 0.68 | KDM4E (0.44) | KDM4EADAM17LMNAMEN1KMT2A | |
| SCHEMBL28964800 | 0.68 | CYP3A4 (0.54) | KDM4ELMNAMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743818-B2 | TREATING ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2004-06-01 | — | — | US | disclosed |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | PEGLION JEAN-LOUIS (FR) | 2003-02-13 | — | — | US | disclosed |
| US-6452015-B2 | FOR TREATMENT OF ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | HRH4, HTR4, CNR1 | KDM4E 1243/4885ADAM17 4466/4885LMNA 2513/4885 |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | CYP2W1, HRH4, CNR1 | KDM4E 2090/4885ADAM17 4375/4885LMNA 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.